Astrana Health, Inc. (ASTH)
(Delayed Data from NSDQ)
$54.53 USD
+0.75 (1.39%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $54.52 -0.01 (-0.02%) 7:58 PM ET
4-Sell of 5 4
C Value A Growth C Momentum B VGM
Income Statements
Fiscal Year end for Astrana Health, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 1,387 | 1,144 | 774 | 687 | 561 |
Cost Of Goods | 1,172 | 945 | 596 | 539 | 468 |
Gross Profit | 215 | 199 | 178 | 148 | 93 |
Selling & Adminstrative & Depr. & Amort Expenses | 130 | 95 | 80 | 67 | 60 |
Income After Depreciation & Amortization | 85 | 104 | 98 | 81 | 32 |
Non-Operating Income | 21 | -10 | -15 | 107 | -2 |
Interest Expense | 16 | 8 | 5 | 10 | 5 |
Pretax Income | 90 | 87 | 78 | 178 | 26 |
Income Taxes | 32 | 36 | 28 | 56 | 8 |
Minority Interest | -3 | 1 | -25 | 84 | 4 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | 58 | 51 | 49 | 122 | 18 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | 61 | 49 | 74 | 38 | 14 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | 103 | 123 | 117 | 100 | 53 |
Depreciation & Amortization (Cash Flow) | 19 | 18 | 19 | 20 | 21 |
Income After Depreciation & Amortization | 85 | 104 | 98 | 81 | 32 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 47.07 | 45.42 | 45.31 | 37.49 | 36.40 |
Diluted EPS Before Non-Recurring Items | 1.29 | 1.16 | 1.63 | 1.01 | 0.43 |
Diluted Net EPS (GAAP) | 1.29 | 1.08 | 1.63 | 1.01 | 0.39 |
Fiscal Year end for Astrana Health, Inc falls in the month of December .
All items in Millions except EPS data.
9/30/24 | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | |
---|---|---|---|---|---|
Sales | NA | 486.27 | 404.36 | 353.04 | 348.17 |
Cost Of Goods | NA | 412.81 | 330.40 | 314.06 | 275.38 |
Gross Profit | NA | 73.46 | 73.96 | 38.98 | 72.80 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 43.39 | 43.82 | 42.85 | 33.72 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | 30.07 | 30.14 | -3.87 | 39.08 |
Non-Operating Income | NA | 10.42 | 1.45 | 10.22 | 2.71 |
Interest Expense | NA | 8.59 | 7.59 | 5.42 | 3.78 |
Pretax Income | NA | 31.90 | 24.00 | 0.92 | 38.02 |
Income Taxes | NA | 10.03 | 7.14 | 2.84 | 10.04 |
Minority Interest | NA | 2.70 | 2.03 | -12.78 | 5.91 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | 21.87 | 16.86 | -1.91 | 27.97 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | 19.17 | 14.84 | 10.87 | 22.06 |
Earnings Per Share Data | 9/30/24 | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 |
---|---|---|---|---|---|
Average Shares | NA | 47.54 | 47.85 | 47.52 | 46.92 |
Diluted EPS Before Non-Recurring Items | NA | 0.40 | 0.31 | 0.26 | 0.47 |
Diluted Net EPS (GAAP) | NA | 0.40 | 0.31 | 0.23 | 0.47 |